Bv8 regulates myeloid-cell-dependent tumour angiogenesis

By F. Shojaei, Xiumin Wu, Cuiling Zhong, Lanlan Yu, Xiao-huan Liang, Jenny Yao, D. Blanchard, C. Bais, Franklin V. Peale, Nicholas van Bruggen and 6 more. Nature, 2007

645 citations recorded by the source corpus.

Subfields: Cancer Research, Cell Biology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/3fffdad17b66a5841ea47d575becd4ac9e7c4c59

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. J. Pollard
2. A. Mantovani
3. Xiumin Wu
4. Cuiling Zhong
5. Zena Werb
6. A. Sica
7. N. Vasudev
8. N. Ferrara

In Cell Biology

1. A. Sica
2. P. Allavena
3. C. Garlanda
4. J. Pollard
5. Zena Werb
6. M. Demaria

In Molecular Biology

1. A. Mantovani
2. Zena Werb
3. A. Sica
4. J. Pollard
5. P. Allavena
6. F. Balkwill
7. C. Lewis
8. Xiumin Wu

Citations in the corpus

• Tumor associated macrophages and neutrophils in cancer. (2013, background): “Accordingly, blocking Bv8 reduced peripheral blood and umor-infiltrating neutrophils, suppressed angiogenesis and tumor rowth (Shojaei et al. 2007).”
• Cancer-related inflammation (2008, background): “The pro-angiogenic protein vascular endothelial growth factor (VEGF) and related molecules are potent monocyte attractants and contribute to the recruitment of monocytes into primary tumours and the metastatic nich”
• The role of myeloid cells in the promotion of tumour angiogenesis (2008, background): “MDSC have also been detected in experimental murine tumour”
• Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. (2008, background): “MDSCs have been implicated in tumor refractoriness to anti-VEGF treatment and likely contribute to TGF-a-mediated metastasis (Shojaei et al., 2007a; Yang et al., 2008).”
• Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions (2014, background): “Pre-clinical studies have identified numerous candidates including angiopoietins [129], Bv8; Bombina variagata peptide 8 [134], EGF; epidermal growth factor [135], the DeltaNotch pathway [136], FGF1 and FGF2; fibroblast growth factors 1 and 2 [137, 138], HGF; hepatocyte growth factor [139], IL-8; in”